No Data
Candel Therapeutics Poised for Breakthrough in Cancer Therapies, Key Trials to Read Out by Year-End | NASDAQ:CADL
This Insider Has Just Sold Shares In Candel Therapeutics
Candel Therapeutics to Present Preclinical Data on Therapeutic Potential of CAN-3110 in Melanoma at SITC 2024 Annual Meeting
Candel Therapeutics, Inc. (NASDAQ:CADL) Most Popular Amongst Individual Investors Who Own 48%, Insiders Hold 30%
Express News | Milestone Pharmaceuticals Appoints Industry Veteran Joseph Papa to Its Board of Directors
Candel Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference